28.5% Salicylic Acid

Manufacturer
Elorac, Inc. | Swiss-American CDMO, LLC
Effective date
2018-04-06
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:25:41

Label at a glance#

Product28.5% Salicylic Acid
Active ingredientsalicylic acid
Label structure3 sections

Label contents#

Full prescribing information#

28.5% Salicylic Acid Extended Release Antiviral Film-Forming Solution: Package Insert

SPL PATIENT PACKAGE INSERT SECTION

SPL UNCLASSIFIED SECTION

Rx only

FOR TOPICAL USE ONLY.

NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

DESCRIPTION

DESCRIPTION SECTION

This Product is a topical preparation containing 28.5% salicylic acid extended release in a proprietary film-forming virucidal solution composed of acrylates copolymer, butyl acetate, carthamus tinctorius seed oil, cocamidopropyl dimethylamine, ethylhexylglycerin, isopropyl alcohol, isopropyl-metacresol, olea europaea fruit oil, phenic acid, phenoxyethanol, polysorbate 80, polyvinyl butyral, trimethyl pentanyl diisobutyrate, and water. The pharmacologic activity of the Product is generally attributed to the keratolytic activity of salicylic acid, which is incorporated into a polyacrylic, film-forming virucidal solution designed to cover the wart without the need for a bandage. The structural formula of salicylic acid is:

5-01.jpg
5-01.jpg

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Although the exact mode of action for salicylic acid in the treatment of warts is unknown, its activity appears to be associated with its keratolytic action, which results in mechanical removal of epidermal cells infected with wart viruses. This Product incorporates a unique patented extended release form of salicylic acid that provides for enhanced release of salicylic acid for over 24 hours.

The virucidal complex incorporated into this Products proprietary solution is designed to help reduce risk of reinfection at the wart site, as well as prevent viral contamination of the product under normal usage.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

This Product is indicated for the topical treatment and removal of common warts and plantar warts.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients with diabetes or impaired blood circulation should not use the Product. This Product also should not be used on moles, birthmarks, and unusual warts with hair growing from them, or warts on the face.

PRECAUTIONS

PRECAUTIONS SECTION

This Product is for external use only. Do not permit it to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. The Product should not be allowed to contact normal skin surrounding the wart site, since localized irritation may occur. Treatment should be discontinued if excessive irritation occurs.

The Product is flammable. Keep away from fire or flame. Keep bottle tightly capped when not in use.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

A localized irritant reaction may occur if this Product is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Prior to applying the Product, soak wart in warm water for five minutes. Remove any loose tissue by gently rubbing with a washcloth, emery board, or pumice stone. Dry the wart site thoroughly. Using the brush applicator supplied, apply it twice to the entire wart surface, allowing the first application to dry before applying the second. Continue treatment once or twice a day as directed by your healthcare provider. Be careful not to apply to surrounding skin.

Clinically visible improvement normally occurs during the first or second week of therapy. Resolution may be expected after four to six weeks of the Product use, though some warts may take longer to remove.

HOW SUPPLIED

HOW SUPPLIED SECTION

This Product is supplied in 10 mL amber bottles with a brush applicator (NDC 42783-324-10).

Store at 15° to 30°C (59° to 86°F).

Manufactured for:

Elorac, Inc.

Vernon Hills, IL 60061

U.S. Patent No. 6,979,440

Additional Patent Pending

© 2014 Elorac, Inc.

1/2018

211909

PATIENT INSTRUCTIONS

PATIENT MEDICATION INFORMATION SECTION

Your health care provider has prescribed this Product, a topical prescription preparation for the treatment of common warts and plantar warts. In order for it to work properly and to ensure maximum benefit, the following instructions should be followed carefully. Of course, as with any medication, always consult your health care provider if you experience any discomfort or unexpected reactions.

STEP 1

WASH

  • Soak wart area in warm water for about 5 minutes.
  • Remove any loose tissue using a washcloth, emery board, or pumice stone.
  • Dry thoroughly.

5-04.jpg5-04.jpg

STEP 2

BRUSH

  • Using the brush applicator supplied, apply twice to entire wart surface, allowing the first application to dry before applying the second.
  • Be careful not to apply to surrounding skin.
  • Leave the Product on wart area after it dries.

5-05.jpg5-05.jpg

Repeat Step 1 and Step 2 once or twice daily as advised by the health care provider.

Clinically visible improvement will normally occur during the first or second week of therapy. Resolution may be expected after four to six weeks of the Product use, though some warts may take longer to remove.

5-07.jpg5-07.jpg

Vernon Hills, IL 60061

28.5% Salicylic Acid Extended Release Antiviral Film-Forming Solution:  Container Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-324-10

28.5% Salicylic Acid Extended Release Antiviral Film-Forming Solution

1/3 fl. oz. (10 mL)

Rx only

bottle-label.jpgbottle-label.jpg

28.5% Salicylic Acid Extended Release Antiviral Film-Forming Solution: Carton Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-324-10

28.5% Salicylic Acid Extended Release Antiviral Film-Forming Solution

1/3 fl. oz. (10 mL)

Rx only

carton-label.jpgcarton-label.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1487371salicylic acid 28.5 % Topical SolutionPSN1
1487371salicylic acid 285 MG/ML Topical SolutionSCD1
1487371salicylic acid 28.5 % Topical SolutionSY1

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
dea2eded-d1e7-46bb-9a3d-f8dc20de6277Product name120190408

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
42783-324-102020-01-31C16284748780-19d75b9d0-d510-f424-e053-dadaa90a57ce00350fc0-b8db-47e5-8164-0ab539e1c642

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
42783-324-1028.5% Salicylic Acid1 in 1 CARTONSOLUTION11
42783-324-1028.5% Salicylic Acid10 mL in 1 BOTTLE, WITH APPLICATORSOLUTION101

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42783-32428.5% SALICYLIC ACID (SALICYLIC ACID) SOLUTION [ELORAC, INC.]1Legacy NDC, 2 package rows20180430_00350fc0-b8db-47e5-8164-0ab539e1c642.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42783-32442783-324-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
salicylic acidO414PZ4LPZACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
fb43c2d8-731b-437c-ba5c-82e7b8dbe71200350fc0-b8db-47e5-8164-0ab539e1c6422018-04-06Adverse reactionsExact identifier
spl id: fb43c2d8-731b-437c-ba5c-82e7b8dbe712
spl set id: 00350fc0-b8db-47e5-8164-0ab539e1c642

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.